CATALOGO DEI PRODOTTI DELLA RICERCA

SCAFFIDI, Luigi
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.883
EU - Europa 2.044
AS - Asia 1.881
SA - Sud America 304
Continente sconosciuto - Info sul continente non disponibili 97
AF - Africa 52
OC - Oceania 34
AN - Antartide 1
Totale 7.296
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.790
RU - Federazione Russa 905
SG - Singapore 701
CN - Cina 551
GB - Regno Unito 303
BR - Brasile 246
IT - Italia 235
HK - Hong Kong 184
VN - Vietnam 163
DE - Germania 128
SE - Svezia 111
FR - Francia 110
IE - Irlanda 93
KR - Corea 57
BD - Bangladesh 51
CA - Canada 45
IN - India 43
FI - Finlandia 38
AU - Australia 33
MX - Messico 25
PL - Polonia 24
AR - Argentina 21
TR - Turchia 20
ID - Indonesia 19
UA - Ucraina 17
JP - Giappone 16
NL - Olanda 16
CO - Colombia 14
IQ - Iraq 13
ZA - Sudafrica 9
AT - Austria 8
BE - Belgio 7
DZ - Algeria 7
PH - Filippine 7
SA - Arabia Saudita 7
UZ - Uzbekistan 7
VE - Venezuela 7
ES - Italia 6
NG - Nigeria 6
TN - Tunisia 6
AE - Emirati Arabi Uniti 5
CG - Congo 5
CL - Cile 5
DK - Danimarca 5
MA - Marocco 5
MY - Malesia 5
PK - Pakistan 5
TG - Togo 5
CH - Svizzera 4
CR - Costa Rica 4
JO - Giordania 4
LT - Lituania 4
PE - Perù 4
AL - Albania 3
AZ - Azerbaigian 3
CZ - Repubblica Ceca 3
EC - Ecuador 3
EE - Estonia 3
EU - Europa 3
JM - Giamaica 3
KE - Kenya 3
LV - Lettonia 3
RO - Romania 3
BY - Bielorussia 2
ET - Etiopia 2
GR - Grecia 2
GT - Guatemala 2
HN - Honduras 2
MD - Moldavia 2
NO - Norvegia 2
NP - Nepal 2
OM - Oman 2
PR - Porto Rico 2
SI - Slovenia 2
SY - Repubblica araba siriana 2
TT - Trinidad e Tobago 2
TW - Taiwan 2
UY - Uruguay 2
AM - Armenia 1
AO - Angola 1
AQ - Antartide 1
BA - Bosnia-Erzegovina 1
BB - Barbados 1
BG - Bulgaria 1
BH - Bahrain 1
BO - Bolivia 1
CI - Costa d'Avorio 1
CY - Cipro 1
DM - Dominica 1
DO - Repubblica Dominicana 1
GD - Grenada 1
GE - Georgia 1
IL - Israele 1
IR - Iran 1
KH - Cambogia 1
LB - Libano 1
LK - Sri Lanka 1
LY - Libia 1
MM - Myanmar 1
MQ - Martinica 1
Totale 7.191
Salva come PNG Salva come JPEG
Città #
Ashburn 426
Singapore 358
San Jose 309
Chandler 293
Moscow 288
Dallas 245
Southend 229
Hong Kong 182
Beijing 148
Council Bluffs 126
Dublin 93
The Dalles 86
Woodbridge 83
Verona 75
Los Angeles 55
New York 53
Ho Chi Minh City 49
Ann Arbor 48
Wilmington 41
Lawrence 40
Princeton 40
Santa Clara 39
Jinan 34
Shenyang 34
Hanoi 31
Jacksonville 31
São Paulo 29
Buffalo 26
Perth 26
Sindelfingen 26
Nanjing 25
Columbus 23
Munich 23
Montreal 20
Redondo Beach 19
Warsaw 18
Tokyo 16
Phoenix 15
Tianjin 15
Chennai 14
Helsinki 14
Nuremberg 14
Orem 14
San Francisco 14
Falls Church 13
Rome 13
Toronto 13
Zhengzhou 13
Hebei 12
Houston 12
London 12
Taiyuan 12
Milan 11
Poplar 11
Atlanta 10
Bologna 10
Changsha 10
Mexico City 10
Redmond 10
Seattle 10
Seoul 10
Chicago 9
Dong Ket 9
Guangzhou 9
Jakarta 9
Nanchang 9
Redwood City 9
Belo Horizonte 8
Denver 8
Rio de Janeiro 8
Stockholm 8
Brussels 7
Frankfurt am Main 7
Norwalk 7
Porto Alegre 7
Taizhou 7
Tashkent 7
Thái Nguyên 7
Ankara 6
Brasília 6
Chengdu 6
Haikou 6
Haiphong 6
Kent 6
Kyiv 6
New Delhi 6
Ningbo 6
Querétaro 6
Shanghai 6
Washington 6
Abuja 5
Amsterdam 5
Basingstoke 5
Buenos Aires 5
City of London 5
Da Nang 5
Düsseldorf 5
Falkenstein 5
Johannesburg 5
Lomé 5
Totale 4.236
Salva come PNG Salva come JPEG
Nome #
BCR-ABL fusion transcript b2a2 is associated with a higher risk of non-optimal early response in CP-CML patients treated with standard dose imatinib: a study from Gruppo Triveneto LMC. 281
CAL2 Monoclonal Antibody Is a Rapid and Sensitive Assay for the Detection of Calreticulin Mutations in Essential Thrombocythemia and May Provide Prognostic Informations 254
Anaphylactic Reactions After Discontinuation of Hymenoptera Venom Immunotherapy: A Clonal Mast Cell Disorder Should Be Suspected 247
Predictors for response to ruxolitinib in real-life: an observational independent study on 266 patients with myelofibrosis 228
Predictors of stable deep molecular response in chronic phase chronic myeloid leukemia patients treated with dasatinib or nilotinib after imatinib failure 217
Predictive factors of stable deep molecular response in chronic myeloid leukemia patients treated with imatinib standard dose: a study from the Gruppo Triveneto LMC. 216
Combination of EUTOS score and 3-month BCR-ABL transcript level identifies a group of good-risk chronic myeloid leukemia patients with favorable response to frontline imatinib therapy 196
Digital PCR improves the quantitation of DMR and the selection of CML candidates to TKIs discontinuation 193
Comparison of dasatinib and nilotinib as second-line therapy after imatinib failure in chronic phase chronic myeloid leukemia patients. 192
CAL2 monoclonal antibody is a rapid and sensitive assay for the detection of calreticulin mutations in essential thrombocythemia patients 192
Regulative Loop between β-catenin and Protein Tyrosine Receptor Type γ in Chronic Myeloid Leukemia 191
The serological prevalence of SARS-CoV-2 infection in patients with chronic myeloid leukemia is similar to that in the general population 189
Real-life comparison of dasatinib and nilotinib as second-line therapy after imatinib failure for chronic phase CML 186
Predictors for Response to Ruxolitinib in Real-Life: An Observational Independent Study on 408 Patients with Myelofibrosis 186
Baseline factors associated with response to ruxolitinib: an independent study on 408 patients with myelofibrosis 185
Imatinib-treated chronic myeloid leukemia patients with discordant response between cytogenetic and molecular tests at 3 and 6 month time-points have a reduced probability of subsequent optimal response 179
A successful treatment-free remission is achievable also by chronic myeloid leukemia patients lacking optimal requirements 170
Differences in presenting features, outcome and prognostic models in patients with primary myelofibrosis and post-polycythemia vera and/or post-essential thrombocythemia myelofibrosis treated with ruxolitinib. New perspective of the MYSEC-PM in a large multicenter study⁎ 165
Excellent outcomes of 2G-TKI therapy after imatinib failure in chronic phase CML patients 164
Efficacy and safety of ruxolitinib in intermediate-1 IPSS risk myelofibrosis patients: Results from an independent study 162
Arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life practice are predicted by the Systematic Coronary Risk Evaluation (SCORE) chart 161
Epidemiology, outcome, and risk factors for infectious complications in myelofibrosis patients receiving ruxolitinib: A multicenter study on 446 patients 159
Benefit-risk profile of cytoreductive drugs along with antiplatelet and antithrombotic therapy after transient ischemic attack or ischemic stroke in myeloproliferative neoplasms 158
Prospective assessment of NGS-detectable mutations in CML patients with nonoptimal response: the NEXT-in-CML study 156
Arterial thrombosis in Philadelphia-negative myeloproliferative neoplasms predicts second cancer: a case-control study 153
Bosutinib in the real-life treatment of chronic myeloid leukemia patients aged $greater$65~years resistant/intolerant to previous tyrosine-kinase inhibitors 150
SETD2 and histone H3 lysine 36 methylation deficiency in advanced systemic mastocytosis 149
Cardiovascular toxicity in patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors in the real-life practice: Identification of risk factors and the role of prophylaxis 143
BCR::ABL1 levels at first month after TKI discontinuation predict subsequent maintenance of treatment‐free remission: A study from the “GRUPPO TRIVENETO LMC” 136
Impact of comorbidities and body mass index in patients with myelofibrosis treated with ruxolitinib 124
Safety and efficacy of switching from branded to generic imatinib in chronic phase chronic myeloid leukemia patients treated in Italy 124
Second primary malignancy in myelofibrosis patients treated with ruxolitinib 120
Life after ruxolitinib: Reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis 117
Low low-density lipoprotein (LDL), cholesterol and triglycerides plasma levels are associated with reduced risk of arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life. A Campus CML study 117
Imatinib and polypharmacy in very old patients with chronic myeloid leukemia: effects on response rate, toxicity and outcome 114
Favorable outcome of chronic myeloid leukemia co-expressing e13a2 and e14a2 transcripts, treated with nilotinib 114
Deferasirox in the management of iron overload in patients with myelofibrosis treated with ruxolitinib: The multicentre retrospective {RUX}-{IOL} study 111
Management of Chronic Myeloid Leukemia in Advanced Phase 110
Renin angiotensin system inhibitors reduce the incidence of arterial thrombotic events in patients with hypertension and chronic myeloid leukemia treated with second- or third-generation tyrosine kinase inhibitors 89
Long-term mortality rate for cardiovascular disease in 656 chronic myeloid leukaemia patients treated with second- and third-generation tyrosine kinase inhibitors 85
Second cancers in MPN: Survival analysis from an international study 84
Ropeginterferon versus Standard Therapy for Low-Risk Patients with Polycythemia Vera 77
Successful Preservation of Native BCR::ABL1 in Chronic Myeloid Leukemia Primary Leukocytes Reveals a Reduced Kinase Activity 75
Second cancer in Philadelphia negative myeloproliferative neoplasms (MPN-K). A nested case-control study 75
Incidence of blast phase in myelofibrosis patients according to anemia severity at ruxolitinib start and during therapy 75
The new Systematic Coronary Risk Evaluation (SCORE2 and SCORE2-OP) estimates the risk of arterial occlusive events in chronic myeloid leukemia patients treated with nilotinib or ponatinib 74
Recurrent arterial occlusive events in patients with chronic myeloid leukemia treated with second- and third-generation tyrosine kinase inhibitors and role of secondary prevention 72
Ropeginterferon phase 2 randomized study in low-risk polycythemia vera: 5-year drug survival and efficacy outcomes 67
Refined diagnostic criteria for bone marrow mastocytosis: a proposal of the European competence network on mastocytosis 55
Ruxolitinib in cytopenic myelofibrosis: Response, toxicity, drug discontinuation, and outcome 43
Digital PCR (dPCR) is able to anticipate the achievement of stable deep molecular response in adult chronic myeloid leukemia patients: results of the DEMONSTRATE study 16
Totale 7.296
Salva come PNG Salva come JPEG
Categoria #
all - tutte 26.916
article - articoli 21.702
book - libri 0
conference - conferenze 5.214
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 53.832
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022181 0 0 0 40 10 10 6 14 11 2 14 74
2022/2023711 42 82 69 121 72 167 3 41 77 11 14 12
2023/2024398 11 36 19 52 33 32 14 18 10 41 102 30
2024/20251.078 46 57 39 187 60 39 83 76 137 67 97 190
2025/20263.331 217 188 206 542 838 192 287 179 306 209 38 129
2026/2027549 46 115 143 245 0 0 0 0 0 0 0 0
Totale 7.296